Navigation Links
Adeona Reports Third Quarter 2011 Financial Results
Date:11/14/2011

ts presented in April 2011 from the clinical study evaluating our medical food, reaZin™, an apparent cognitive benefit was observed in older patients.
  • Preparations are underway to conduct a larger clinical study of AEN-100 (our zinc-based drug candidate) under an IND application in patients with mild to moderate Alzheimer's disease who are age 70 and older. It is anticipated that the clinical study will enroll just over 100 patients and that the evaluation period will be at least 12 months.

Product Development Programs

Reducing the Duration and Symptoms of the Common Cold

  • On November 4, 2011, we executed an agreement with F&F Foods of Chicago, Illinois, to provide commercial-scale manufacturing of wellZin.

  • On August 25, 2011, George A. Eby, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, was appointed as a member of our Scientific Advisory Board.

Dietary Management of Zinc Deficiency Associated with Alzheimer's Disease

  • In April 2011, clinical study results were presented that demonstrated, on average, that the cognitive function of the placebo group, declined over six months in comparison to patients managed with reaZin, a medical food. The cognitive function trends favoring the patients managed with reaZin were observed in all three standardized cognitive tests utilized in our study and suggest that reaZin may provide an important benefit to the dietary management of zinc deficiency associated with Alzheimer's disease.

  • Based on the results of our clinical study, we are developing reaZin as a medical food for the dietary management of zinc deficiency associated with A
    '/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
2. Adeona Senior Vice President of Research & Development to Present at American College of Nutrition Annual Meeting
3. Adeona Appoints Jeff Lucero Riley as Independent Chairman
4. Adeonas Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease is Hot Topic at 2011 California ALS Research Summit
5. Adeona Announces Completion of Planned Enrollment in Phase II Multiple Sclerosis Clinical Trial
6. Adeona Appoints George A. Eby to Scientific Advisory Board
7. Adeona Reports Second Quarter 2011 Financial Results
8. Adeona to Host Second Quarter 2011 Investor Conference Call
9. Adeona Executes Agreement to Initiate Phase IIb Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrigs Disease (ALS)
10. Adeona Reports 1st Quarter 2011 Financial Results
11. Adeona to Host First Quarter 2011 Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Cynosure, Inc. (Nasdaq: CYNO ... treatment systems for high-volume applications, today reported financial results ... 2014 financial results incorporate the acquisition of Palomar Medical ... Second-Quarter 2014 Financial Highlights ... , Non-GAAP net income of $7.1 million, or ...
(Date:7/29/2014)... 2014   What:   ... present data from a Phase I clinical trial of ... stop Parkinson,s disease progression. The Michael J. Fox Foundation ... will discuss the impact of the results for patients ... July 31, 2014         ...
(Date:7/29/2014)... , July 29, 2014  Drug development for ... rising incidence rates and the intense need for ... vaccine. Change is underway as the market moves ... highly effective, easily-tolerated, interferon-free oral therapies. ... Gilead,s mega blockbuster Sovaldi is the first ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... previously announced underwritten public offering of 16,300,000 shares of ... per share to the public. The gross proceeds to ... $130,400,000, before deducting underwriting discounts and commissions, and other ...
... 26, 2011 American Scientific Resources, Inc. (OTCQB: ASFX) ... and Sanomedics International Holdings, Inc., and its affiliates, have ... United States District Court for the Southern District of ... judge, Hon. Ursula Ungaro, and the case has been ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3American Scientific Resources, Inc. Announces Dismissal of Sanomedics International Holdings, Inc. lawsuit 2
(Date:7/30/2014)... According to the Yeast Infection No More ... guide that will help candida sufferers get rid of their ... book uncovers to readers the truth about yeast infection and ... book, people will discover natural and safe remedies to relieve ... burning, and irritation of the vagina or vulva. , ...
(Date:7/30/2014)... 2014 The San Diego personal injury lawyers ... announcing that they are now offering free case reviews for ... asbestos exposure. , “Symptoms of asbestos exposure can take years ... 30 plus years ago may just now be suffering from ... Office of Melinda J. Helbock A.P.C. “We want people to ...
(Date:7/29/2014)... 30, 2014 VisitandCare.com today ... been added to the company’s exclusive network to help ... of joint efforts — as top fertility clinics in ... offer affordable, state-of-the-art, and successful IVF treatments. , The ... a comprehensive study by professionals at VisitandCare.com. The goal ...
(Date:7/29/2014)... Angeles, California (PRWEB) July 29, 2014 ... Education’ to senior communities with focus on Brain ... Aegis Living in Ventura. Brain Fitness Program Director ... lecture to Aegis Memory Care unit and the ... separate sessions. Aegis Life Enrichment Director Christy Rozsa ...
(Date:7/29/2014)... Hopkins researchers say they have discovered a chemical alteration ... that, if confirmed in larger studies, could give doctors ... risk of attempting suicide. , The discovery, described online ... that changes in a gene involved in the function ... significant role in turning what might otherwise be an ...
Breaking Medicine News(10 mins):Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 2Health News:Yeast Infection No More Book Review Exposes Linda Allen's Guide for Treating Yeast Infection – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 2Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 3Health News:1Heart Caregiver Services Conducts Brain Fitness Education and Brings Tee Barr to Aegis Ventura 4Health News:A blood test for suicide? 2Health News:A blood test for suicide? 3
... Bolling Air Force Base in Washington D.C., as well as a lecture ... ... Washington, D.C. (Vocus) July 2, 2008 -- The Drug Enforcement Administration ... Richard Nixon, who through an Executive Order established a single unified command ...
... QuadraBloc™, a new and improved version of AmWay's MagnaBloc. , ... ... a long-popular form of pain management, is now available in a ... ,"QuadraBloc has already been released in the United States, and will ...
... will be October 24-26, 2008 at the Catholic Institute in Toulouse, ... knowledge, ideas, applications and prospective issues in an interactive and collaborative ... http://www.ifats08.org for details. , ... Carmel, IN (PRWEB) ...
... using a combination of drugs targeting different parts of ... with severe lupus involving the kidneys, according to a ... Society of Nephrology (JASN). , "In our study, ... therapy for inducing complete remission of class V+IV lupus ...
... Clearance of Uniquely Integrated Meter/Pump System with ... and Compatible Software, WEST CHESTER, Pa., July ... its OneTouch(R) Ping(TM) Glucose Management System,by the U.S. ... the first,full-feature insulin pump that wirelessly communicates with ...
... of 300 human genomes in just over six months. The ... of genetic code that will be read by researchers worldwide, ... and disease. Scientists will be able to answer questions unthinkable ... be transformed. , The amount of data is remarkable: ...
Cached Medicine News:Health News:New MagnaBloc™ Product Available from Gradient Medical 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 2Health News:2008 International Federation of Adipose Therapeutics and Science (IFATS) Conference Date Set 3Health News:'Multi-target' immune therapy improves outcomes of severe lupus nephritis 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 2Health News:OneTouch(R) Ping(TM) Glucose Management System Cleared by FDA 3Health News:15 human genomes each week 2Health News:15 human genomes each week 3
... The new Guidant VASOVIEW® HemoPro™ ... deliver a new level of ... for both the saphenous vein ... cut-and-seal capability, it lets you ...
Patient Monitor...
...
... or antepartum GBS results can be available in ... revolutionary in vitro diagnostic test is the first ... in the clinical lab and near-patient by non-laboratory ... 24 hours a day, 365 days a year. ...
Medicine Products: